What to Expect from Wegovy: a Realistic Week-by-Week Picture

Appetite suppression is usually the earliest change — often noticeable in the first one to two weeks, before significant weight loss begins.
Wegovy is titrated through five dose steps (0.25mg up to 2.4mg weekly, or 7.2mg where clinically appropriate), with each level held for around four weeks to reduce side effects.
Clinical trial evidence from the STEP 1 study published in the New England Journal of Medicine reported an average body-weight reduction of around 15% over 68 weeks at 2.4mg.
Most side effects are gastrointestinal, tend to peak after a dose increase, and typically ease within days to a couple of weeks as the body adjusts.

Most people starting Wegovy notice their appetite beginning to change within the first few weeks, though meaningful weight loss typically builds gradually over several months. Semaglutide 2.4mg works by activating GLP-1 receptors that regulate hunger and slow how quickly food leaves the stomach — and its effects compound as the dose increases. These are prescription-only medicines; a clinician assesses whether Wegovy is right for you before any treatment begins. The NHS medicines page for semaglutide gives a clear overview of how the treatment works and what side effects to watch for.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How Wegovy's effects unfold in practice, appetite, weight loss and side effects over time

Step 1: the first four weeks, settling in, not slimming fast

Wegovy starts at 0.25mg weekly. That opening dose is a tolerability step: its job is to let your system adjust to the medicine, not to deliver immediate results. Some people feel a noticeable drop in hunger within the first week or two; others find the effect subtle at first. Either is normal.

Nausea is the most commonly reported early experience, particularly in the days following each injection. It tends to be mild-to-moderate and often passes within a few days. Keeping meals smaller, eating slowly and avoiding very fatty or rich foods makes a real difference. Some people find keeping the pen in the same spot in the fridge door (next to where they keep the milk) helps build the routine of weekly injecting at the same time each week.

Weight loss in week one through four is rarely dramatic. If you're not seeing the scales move much yet, that's expected. The appetite changes happening under the surface are laying the groundwork. For a detailed look at what the opening days feel like, our guide to Wegovy week one covers the practicalities, and if you want to look further ahead, our guide to what to expect in week two of Wegovy walks through how the experience typically shifts once that first injection is behind you.

One thing worth knowing early: Wegovy is a prescription medicine and every step of treatment, including dose increases, is reviewed by a prescriber. There are no automatic changes.

Step 2: months two to four, dose increases and appetite shift

From 0.25mg, the schedule moves through 0.5mg, then 1.0mg, each held for roughly four weeks. Most people begin to notice more consistent appetite suppression from around the 0.5mg mark. Portions feel satisfying sooner. Thinking about food between meals becomes less constant. For many, this is where the experience of Wegovy starts to feel meaningfully different from trying to lose weight without support.

Gastrointestinal side effects can resurface briefly after each dose step up (nausea, loose stools or constipation are most common) before settling again. The pattern tends to repeat with each increase, but most people find the episodes shorter and milder at higher steps because the body has already adapted to the mechanism.

Weight loss typically accelerates through this phase. There is no single trajectory that applies to everyone: age, starting weight, diet, activity levels and individual response to the medicine all shape the result. How long Wegovy takes to work depends on several overlapping factors, and our guide works through the evidence honestly. Progress at five weeks is explored in more detail on the week five page.

Step 3: month four onwards, reaching maintenance and the longer picture

The standard maintenance dose for Wegovy is 2.4mg weekly, reached after around 16 weeks of titration. This is where the STEP 1 trial's results were generated: roughly 15% average weight reduction over 68 weeks, in a study of nearly 2,000 adults with obesity or overweight and a weight-related condition. That figure is a population average, some participants lost considerably more, some less. It gives an honest reference point, not a personal guarantee.

The MHRA also approved a 7.2mg maintenance dose in January 2026, and in April 2026 a dedicated single-dose 7.2mg pen was confirmed, with trials reporting around 20.7% average weight loss at 72 weeks. Whether that higher dose is clinically appropriate for a given patient is a decision made with a prescriber, not a default upgrade. The MHRA's announcement on the 7.2mg pen sets out exactly what was approved and for whom.

At maintenance, the focus shifts: sustaining weight loss requires continuing the medicine alongside realistic eating habits and regular activity. Weight tends to return if treatment stops without those foundations in place. A prescriber reviews continued suitability at every repeat, at nume, that happens before each order, with no automatic renewals. If you're weighing up your options, our treatment overview sets out what's available and how the medicines compare.

For anyone considering starting, our guide to what you can expect from Wegovy walks through the prescription process, side effects and realistic outcomes in full. Suitability, cost context and what the consultation covers are also covered on the Wegovy information page. Questions our prescribers hear most often are gathered on the FAQs page.

If you'd like a clinician to assess whether Wegovy is right for you, start your free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions